| Document |
Document Title |
|
WO/2022/271604A1 |
Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1: (1) or a pharmaceutically-acceptable salt t...
|
|
WO/2022/272124A1 |
Disclosed are hemoglobin-based oxygen carriers (HBOCs) that comprise a polymer-functionalized polymerized hemoglobin, such as a polyalkylene oxide (PAO)-functionalized polymerized hemoglobin, as well as compositions comprising these HBOC...
|
|
WO/2022/269439A1 |
A composition for use in treating a subject with diabetes or pre-diabetes includes an effective amount of a phenyl propionic acid of the Formula (I), an isomer, or a pharmaceutically acceptable salt thereof, and the composition lowers on...
|
|
WO/2022/271658A1 |
The present embodiments provide compounds of Formula (I), compositions of the compounds, and methods for treating diseases such as cancer.
|
|
WO/2022/270972A1 |
Provided are a use, a pharmaceutical composition, and a method for efpeglenatide for reducing a risk of developing a cardiovascular disease or renal dysfunction. The efpeglenatide may be used for cardiovascular or renal protection of pat...
|
|
WO/2022/272106A1 |
The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions ...
|
|
WO/2022/268738A1 |
The present invention relates to a combination comprising at least one monoamine reuptake inhibitor and at least one potassium-chloride cotransporter type 2 expression-enhancing compounds (KEEC). The present invention also relates to a p...
|
|
WO/2022/270523A1 |
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a pyrimidine drug, a platinum formulation, and an angioge...
|
|
WO/2022/269525A1 |
The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pha...
|
|
WO/2022/271547A1 |
The present invention relates to combinations useful in the treatment of cancer. In particular, the present invention relates to a combination comprising a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor) and a lipophilic statin, ...
|
|
WO/2022/268969A1 |
The present invention relates to a cephalosporin for use in a method of preventing and/or treating colon cancer, wherein the cephalosporin comprises a nitrogen, preferably positively charged nitrogen, and a first carboxyl group, preferab...
|
|
WO/2022/269064A1 |
The present invention provides a pharmaceutical combination of nicotinamide riboside with methyl donor(s) for use in a method for treatment of Parkinson's disease (PD) in a human subject; a pharmaceutical composition for use in such meth...
|
|
WO/2022/269264A1 |
A single unit oral dose pharmaceutical composition for use as a medicament for separate, sequential or simultaneous administration with an agonist of a 5- hydroxytryptamine (5-HT) receptor; wherein the single unit oral dose pharmaceutica...
|
|
WO/2022/270760A1 |
The present invention relates to a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating or treating steatohepatitis, comprising a curcumin derivative and a TGF-β receptor inhibitor as active ingredie...
|
|
WO/2022/268056A1 |
Tissue-targeting exosomes and an application thereof. The tissue-targeting exosomes comprise exosomes which target bladder tissue, colorectal tissue, lung tissue, kidney tissue, stomach tissue, liver tissue, heart tissue, pancreatic tiss...
|
|
WO/2022/269066A1 |
The present invention provides nicotinamide riboside for use in a method for treatment of Parkinson's disease (PD) in a human subject; a pharmaceutical composition for use in such method, the composition comprising nicotinamide riboside;...
|
|
WO/2022/270621A1 |
Lysophosphatidic acid (LPA) has been found to function as a mediator that promotes invasiveness in osteosarcoma. In addition, it has been discovered that LPAR1, which is a receptor for LPA, is highly expressed in osteosarcoma and glioma,...
|
|
WO/2022/270612A1 |
The present disclosure provides an anti-CTLA-4 antibody and methods for producing and using same. The present disclosure also provides: a nucleic acid encoding said anti-CTLA-4 antibody; and host cells including said nucleic acid. The pr...
|
|
WO/2022/262624A1 |
The present invention belongs to the field of biomedicine, and relates to a pharmaceutical use of β2-microglobulin or an inhibitor thereof. In particular, the present invention relates to a use of β2-microglobulin or an inhibitor there...
|
|
WO/2022/266285A1 |
Therapeutic methods and pharmaceutical compositions for treating symptoms associated with myeloproliferative neoplasms in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods of treating symp...
|
|
WO/2022/265509A1 |
The invention relates to a pharmaceutical composition, as well as a dosage comprising said pharmaceutical composition, for use in the treatment of a mitochondrial activity related disease or disorder and/or of an adiponectin production r...
|
|
WO/2022/265912A1 |
Antibodies and antibody-drug conjugates that selectively bind to a membrane-associated extracellular portion of a cleaved amphiregulin precursor protein; methods of using the antibodies and antibody-drug conjugates to detect and inhibit ...
|
|
WO/2022/262516A1 |
A linker, comprising an Lb structure fragment, the Lb structure being selected from the following formula, wherein subscript q is selected from any integer from 1 to 20, preferably from 3 to 10, and most preferably from 5 to 8. The prese...
|
|
WO/2022/263792A1 |
The present invention relates to compositions for use in treating or preventing ischaemia reperfusion injury. In particular, the present invention relates to a composition comprising a salt of formula (I): for use in treating or preventi...
|
|
WO/2022/265984A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an NEP inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2022/264456A1 |
This substance, which specifically binds to the PEX domain (hemopexin domain) of MT1-MMP (MMP-14) and inhibits a MT1-MMP-mediated survival signal to active hepatic stellate cells (aHSCs), can reduce or kill the active hepatic stellate ce...
|
|
WO/2022/264184A1 |
Provided is a pharmaceutical solid-in-oil nano-dispersion composition that may include ascorbic acid or a astable derivative thereof, a surfactant coating the ascorbic acid or its derivative and an oil vehicle, wherein the ascorbic acid ...
|
|
WO/2022/264966A1 |
The purpose of the present invention is to provide medical therapy for treating and/or preventing Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, for which radical treatments have not yet been discovered. The present ...
|
|
WO/2022/265950A1 |
Provided herein are combinations comprising: (i) one or more EGFR inhibitors; and (ii) one or more PERK activators, such as the specific EGFR inhibitors and PERK activators described herein. Also provided herein are methods of treating c...
|
|
WO/2022/165260A9 |
Provided herein are compositions and methods for the treatment of cancers using modified TILs, wherein the modified TILs include one or more immunomodulatory agents (e.g, cytokines) associated with their cell surface. The immunomodulator...
|
|
WO/2022/263476A1 |
The present invention relates to combinations of local anesthetics for improved pain relief in patients.
|
|
WO/2022/266370A1 |
Provided herein are formulations comprising a therapeutically effective amount of sparsentan and methods of treating idiopathic pulmonary fibrosis (IPF) by the administration of said formulations.
|
|
WO/2022/261846A1 |
The present invention provides an antibody targeting an AXL protein or an antigen binding fragment thereof, and a preparation method therefor and an application thereof. Further provided are an isolated polynucleotide encoding the antibo...
|
|
WO/2022/263680A1 |
Use of a LAG-3 protein or derivative thereof as part of a combination therapy for the treatment of cancer is described. In particular, (a) a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules, (b) a pro...
|
|
WO/2022/257986A1 |
The present invention relates to the use of a CYP450 inhibitor in inhibiting or killing mites and treating dry eye syndrome. A large number of experiments show that the CYP450 inhibitor can be used for inhibiting and killing mites, can e...
|
|
WO/2022/257439A1 |
A pharmaceutical composition and method for inhibiting formation of N-nitrosodimethylamine (NDMA). Within the expiration date of a pharmaceutical composition comprising one selected from metformin, valsartan, irbesartan, losartan, sumatr...
|
|
WO/2022/261263A1 |
The disclosure provides, in part, a method of treating a neuropsychiatric disorder in a patient in need thereof, comprising administering to the patient an effective amount of an orexin receptor antagonist and further comprising administ...
|
|
WO/2022/257438A1 |
A pharmaceutical composition for inhibiting N-nitrosodimethylamine (NDMA) formation, and a method. In a pharmaceutical composition containing a selection of metformin, valsartan, irbesartan, losartan, sumatriptan, diltiazem, tetracycline...
|
|
WO/2022/258612A1 |
The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
|
|
WO/2022/261181A1 |
The present disclosure relates to polypeptides comprising methionine residues functionalized with amino acid moieties. The present disclosure also relates to compositions comprising the polypeptides disclosed herein. The present disclosu...
|
|
WO/2022/260169A1 |
One aspect of the present invention relates to a preparation comprising (a) a fatty acid and (b) a phospholipid, in which the mass ratio [(a)/(b)] of the content of the component (a) to the content of the component (b) is 0.5 to 3.0, the...
|
|
WO/2022/261301A1 |
The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
|
|
WO/2022/258873A1 |
Disclosed is a nutraceutical combination comprising the following active ingredients: a) L-serine; b) a uridine derivative selected from the group formed by uridine monophosphate, a uridine phosphate, a uridine acid halide with a carboxy...
|
|
WO/2022/258992A1 |
The invention provides compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts thereof for use in the treatment or prevention of hypertension: wherein: R1 and R2 are independently selected from H, halogen, C1-6 alk...
|
|
WO/2022/258693A1 |
An autotaxin (ATX) inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treatment of pancreatic cancer in a patient, optionally wherein the method further comprises administration of a TGF-β pathway inhibitor a...
|
|
WO/2022/261025A1 |
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising orally administering to the patient sotorasib and trametinib once daily, wherein the sotorasib and trametinib are administered to the ...
|
|
WO/2022/258600A1 |
The present invention is directed to a combination of the BRAF inhibitor N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy- phenyl]-3-fluoro-pyrrolidine-l-sulfonamide or a pharmaceutically acceptable salt or solvate thereof with ...
|
|
WO/2022/260132A1 |
The present invention addresses the problem of providing an effective cancer treatment method. Provided is a cancer treatment method in which are combined a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody, etc...
|
|
WO/2022/261459A1 |
The present disclosure provides compositions and methods related to the treatment of non-tuberculous mycobacterial infections in a subject. In particular, the present disclosure provides compositions comprising an anti-malarial agent and...
|
|
WO/2022/259252A1 |
The present invention relates to a method of reducing acne relapse or rosacea relapse rate or severity, by reducing the skin's immunological response, wherein the method comprises administering a topical composition comprising at least o...
|
